NCT04017936View on ClinicalTrials.gov

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Cardiac Sarcoidosis
Interventions
DRUG

Anakinra

Active Treatment

Trial Locations (2)

23298

Virginia Commonwealth University, Richmond

48109

University of Michigan Sarcoidosis Clinic, Ann Arbor

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Virginia Commonwealth University

OTHER

NCT04017936 - Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis | Biotech Hunter | Biotech Hunter